Protein phosphatases in pancreatic islets

Henrik Ortsäter¹,², Nina Grankvist³, Richard E Honkanen⁴ and Åke Sjöholm¹,⁴,⁵

¹Biovation Park Telge, Södertälje, Sweden
²Research Unit, Södertälje Hospital, SE-152 86 Södertälje, Sweden
³Degenerative Disease Program, Sanford-Burnham Medical Research Institute, Del E. Webb Neuroscience, Aging and Stem Cell Research Center, 10901 North Torrey Pines Road, La Jolla, California 92037, USA
⁴Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, Alabama 36688, USA
⁵Department of Internal Medicine, Södertälje Hospital, Södertälje, Sweden

Correspondence should be addressed to Å Sjöholm
Email ake.sjoholm@sodertaljesjukhus.se

Abstract

The prevalence of diabetes is increasing rapidly worldwide. A cardinal feature of most forms of diabetes is the lack of insulin-producing capability, due to the loss of insulin-producing β-cells, impaired glucose-sensitive insulin secretion from the β-cell, or a combination thereof, the reasons for which largely remain elusive. Reversible phosphorylation is an important and versatile mechanism for regulating the biological activity of many intracellular proteins, which, in turn, controls a variety of cellular functions. For instance, significant changes in protein kinase activities and in protein phosphorylation patterns occur subsequent to the stimulation of insulin release by glucose. Therefore, the molecular mechanisms regulating the phosphorylation of proteins involved in the insulin secretory process by the β-cell have been extensively investigated. However, far less is known about the role and regulation of protein dephosphorylation by various protein phosphatases. Herein, we review extant data implicating serine/threonine and tyrosine phosphatases in various aspects of healthy and diabetic islet biology, ranging from control of hormonal stimulus–secretion coupling to mitogenesis and apoptosis.

Key Words

- islet cells
- insulin secretion
- apoptosis
- diabetes
- phosphatase

Type 2 diabetes: a growing epidemic

Type 2 diabetes (T2D) is a syndrome characterized by disordered metabolism, resulting in hyperglycemia. The most common and dreaded long-term complication of diabetes is cardiovascular disease, which accounts for 75–80% of all diabetes-related deaths (Meetoo et al. 2007). Diabetes is widespread and it is the fourth leading cause of death in the USA (Meetoo et al. 2007). The expenses by diabetes have been shown to be a major drain on health- and productivity-related resources for healthcare systems and governments. In the USA alone, the annual cost for diabetes amounts to the considerable sum of $245 billion, of which ~97% is targeted to T2D (American Diabetes Association 2013). Improved glycemia is a main focus of T2D therapy and HbA1c levels of 5–6% (DCCT standard; corresponding to 31–42 mmol/mol by IFCC standard) are recommended treatment goals. However, more than 50% of patients with T2D have a HbA1c level of >7% (53 mmol/mol by IFCC standard) and are thus inadequately controlled (Koro et al. 2004).

Loss of glucose-sensitive insulin secretion of the pancreatic β-cell is an early pathogenic event and contributes significantly to the development of the diabetic state (Ward et al. 1984, Bell & Polonsky 2001, Grimsby et al. 2003). The changes in β-cell function in diabetes include decline in glucose-sensitive insulin
secretory output (Ward et al. 1984), disturbances in pulsatile insulin release (Tengholm & Gylfe 2009), and impaired insulin synthesis (Kahn & Halban 1997). Thus, improvement of β-cell function is a major goal in the clinical management of the disease.

Inadequacy of the pancreatic β-cell also results from a combination of impaired secretory function and insufficient β-cell mass. The ability of the β-cell to expand its proliferative capacity in response to an increased insulin demand may be of critical regulatory significance for the development of diabetes (Sjöhöl 1996, Lee & Nielsen 2009). T2D patients exhibit a reduced β-cell mass, possibly due to increased rates of apoptosis (Butler et al. 2003). Maintaining islet β-cell mass and adequate insulin secretion to meet metabolic demands is crucial to avoid glucose intolerance and the development of T2D.

There is a progressive and relentless deterioration in β-cell function over time in T2D, regardless of therapy allocation, such as insulin, glibenclamide, or metformin treatment (Group 1998a,b), eventually leaving many patients reliant on exogenous insulin replacement therapy.

The role of declining β-cell mass and function in the development of T2D has drawn attention to the need for agents that can halt this process. Moreover, in individuals with established T2D, inhibition of the increased apoptosis may lead to restoration of β-cell mass and it may also prevent pre-diabetic subjects to progress into overt T2D.

Regulation of insulin secretion

Pancreatic β-cells are equipped to rapidly sense ambient glycemia. In order for the cells to respond appropriately with insulin secretion, glucose must be metabolized within the β-cells (Hedeskov 1980, Ashcroft & Rorsman 2012). Glucose rapidly enters the cells via the efficient glucose transporter 2 (GLUT2 (GLUT1 in human islets)) that enables a balance between the extracellular and intracellular concentration of glucose (Meglasson & Matschinsky 1986, Newgard & McGarry 1995). Following entry, glucose is phosphorylated by glucokinase, which acts as a glucose sensor by controlling the amount of glucose that traverses through the glycolytic pathway (Matschinsky et al. 1998). Glucose metabolism results, among other things, in increased production of ATP, leading to an increased ATP:ADP ratio (Detimary et al. 1995), which (such as sulfonylurea drugs) closes the ATP-sensitive K⁺ (K_{ATP}) channels (Ashcroft et al. 1984, Cook & Hales 1984). This causes depolarization of the plasma membrane, opening of voltage-dependent Ca²⁺ channels, and influx of extracellular Ca²⁺. Elevation of cytosolic Ca²⁺ is the main trigger for granule translocation and insulin exocytosis (Jonas et al. 1998). However, experiments indicate that glucose retains an excellent ability to secrete insulin even in the presence of maximally effective concentrations of K⁺ and diazoxide, which acts by opening K⁺ channels (Gemba et al. 1992, Komatsu et al. 1997). Thus, although signaling molecules other than ATP and Ca²⁺ must be involved in glucose sensing in the β-cell, the precise nature by which these complementary signals promote secretion and the K_{ATP}-independent signaling pathways activated by glucose have remained elusive. Insulin secretion is a complex process, tuned by many mechanisms, and has been the topic of excellent reviews (Ashcroft & Rorsman 2012, Rorsman & Braun 2013).

Introduction to reversible protein phosphorylation and protein phosphatases

In 1992, the Nobel Prize in Physiology or Medicine was awarded jointly to Edmond H Fischer and Edwin G Krebs, for their earlier discoveries revealing that the reversible covalent attachment of phosphate to a protein functions as a mechanism to regulate biological activity. The protein that was reversibly phosphorylated was glycogen phosphorylase, and the proteins that catalyzed phosphorylation and dephosphorylation were termed phosphorylase kinase and phosphorylase phosphatase respectively (Sutherland & Wosilait 1955, Fischer et al. 1959, Krebs et al. 1959). Today, this simple reaction, in which a kinase catalyzes the transfer of phosphate from the gamma position of a high energy phosphonucleotide (usually ATP) to the side-chain hydroxyl of a protein (usually serine, threonine, or tyrosine) and a phosphatase catalyzes phosphate hydrolysis, is established as a fundamental, if not paramount, mechanism by which eukaryotic cells regulate virtually all aspects of cell biology. Accordingly, there has been an intensive global effort to identify and characterize the biological roles of these important regulatory enzymes.

Sequence data from the human genome indicate humans express ~520 protein kinases, with ~90 acting as tyr-kinases and 428 acting as ser/thr kinases (Johnson & Hunter 2005). Many kinases are highly conserved in nature. However, the tyrosine kinases appear to have evolved more recently, with the evolution of multicellular eukaryote organisms (Alonso et al. 2004, Johnson & Hunter 2005). To counter these kinases, humans have a nearly equal number (~107) of phospho-tyr-phosphatases, suggesting that each tyr-kinase is countered by a
single tyr-phosphatase (Alonso et al. 2004). In contrast, the number of genes encoding proteins capable of catalyzing the hydrolysis of phospho-ser/thr residues is more limited (~40 genes). Estimates of total protein phosphate from studies using [32P] labeling (Hunter & Sefton 1980, Hunter et al. 1980) or proteomic analysis of phosphorylation sites of human proteins (Olsen et al. 2006) are in agreement, indicating that ~98% of the phosphate in proteins is attached to ser/thr residues, with <2% being attached to tyrosine. Thus, the tyrosine kinases/phosphatases may be viewed as ‘thoroughbreds’ acting extensively only in the restricted arena of multicellular eukaryotes. Ser/thr kinases/phosphatases are more primitive and are more likely to act as the ‘work horses’ of reversible phosphorylation in both single and multicellular eukaryotes. Clearly, both families are important and several excellent reviews focus on ser/thr and tyrosine kinases (Manning et al. 2002, Nolen et al. 2004, Taylor & Kornev 2011, Endicott et al. 2012).

When compared with their kinase counterparts, less is known about the biological roles played by protein phosphatases (PPs). This is due, in part, to technical difficulties associated with accurately measuring protein dephosphorylation, and to early and lingering misconceptions that phosphatases act as simple ‘housekeeping’ or pleiotropic enzymes. Today we know that phosphatases are not simple housekeeping enzymes, rather they play specific, active, and sometimes even dominant roles in controlling both the levels of phosphorylation in cells and the regulation of physiological processes (Alonso et al. 2004). In this review, we will focus on PPs, emphasizing their roles in pancreatic islets.

Phosphotyrosine phosphatases (PTPs) have received the most recognition for playing precise and regulated roles in cell signaling, and the 107 genes-encoding PTPs can be divided into four families (Alonso et al. 2004; Fig. 1). The largest family (class I Cys-base PTPs) contains 99 genes. Class I PTPs share a common catalytic mechanism (Fig. 2). In this reaction, during the cleavage of the scissile P–O bond, a covalent phospho-cysteine intermediate is produced at the catalytic site. Hydrolysis of the cysteinyl-phosphate intermediate is then facilitated by the protonation of phenolic oxygen by a conserved aspartic acid and the positioning of an activated water molecule by a conserved active site, glutamine or serine. Mutation of the conserved aspartic acid to alanine can aid the identification of substrates, by producing substrate-trapping mutants that retain the covalent attachment at the catalytic cysteine (Flint et al. 1997, Blanchetot et al. 2005).

Classification of tyrosine protein phosphatases

Class I Cys-based PTPs

- Classic PTPs
  - Receptor PTPs 21
  - Non-receptor PTPs 23
- DSPs
  - MKPs (11)
  - Atypical (19)
  - Myotubularins (16)
  - PRLs (3)
  - CDC14s (4)
  - Slingshots (3)
  - PTENs (5)

Class II Cys-based PTPs (1)

- ACP1

Class III Cys-based PTPs (3)

- CDC25 (3)

Asp-based PTPs (4)

- Eya (4)

Substrate specificity

Tyr

Thr

Thr, mRNA

Pi(3)P

Ser, Thr

Phosphoinositides

Tyr

Tyr, Thr

Tyr
**Figure 2**
Comparison of PTPase and PPP catalytic mechanism. (A) Schematic representation of PTP-Cys-mediated hydrolysis of substrate derived from the crystal structure of PTP1B (data from Barford et al. 1994). (B) Schematic representation of metal ion-mediated hydrolysis of substrate derived from the crystal structure of PP5C (data from Swingle et al. 2004). The attacking hydroxide W1 is shown in blue and the leaving group of the substrate is in green. The substrate, the planar PO₃ moiety of the transition state, and the phosphate product are all shown in red. Solid lines to the metal ions denote metal–ligand bonds, and solid or dashed wedges indicate metal–ligand bonds directed above or below the plane of the page respectively. Wavy lines to the metal ions indicate strained contacts with poor coordination geometry. Dotted lines indicate hydrogen bonds, and the nearly dissociated axial bonds in the transition state are shown by half-dotted double lines.
The class I PTPs can be further divided into four subgroups, with the most studied subgroup referred to as the classical PTPs (38 genes). Classical PTPs are strictly tyrosine specific and come in two forms, transmembrane PTPases (21 genes) and non-receptor PTPase (17 genes). The transmembrane PTPs have external ‘ligand-binding’ domains, a membrane-spanning domain, and a cytosolic catalytic domain(s). In many ways, these PTPs mimic the general characteristics of receptor-tyrosine kinases, the enzymes that they commonly counter in a cell. The non-receptor PTPs lack the extracellular and transmembrane domains. They are generally cytosolic proteins, some of which are anchored to membranes by prenylation.

The largest and most diverse family (in terms of substrate specificity) of class-I cysteine-based PTPs are called dual-specificity phosphatases (DSPs or DUSPs; 69 genes). DSPs share the cysteine-based catalytic mechanism, and as their name implies can act on phosphotyrosine and phosphothreonine sites on MAPKs. Eleven DSPs have MAPK-targeting motifs and may act exclusively at specific phosphotyrosine or phosphothreonine sites on MAPKs. Nineteen are considered atypical DSPs and they represent a poorly characterized family of enzymes that lack MAPK-targeting motifs (Alonso et al. 2004). PTENs (five genes) and myotubularins (16 genes) are present in the DSP family, but they appear to have evolved to specifically dephosphorylate the D3-phosphate of inositol phospholipids (Wishart & Dixon 2002).

The human genome has only one gene encoding a class II cysteine-based PTPs (ACP1), which encodes a low (18 kDa) molecular weight protein. Humans express three class III cysteine-based PTPs, which encode CDC25A, CDC25B, and CDC25C. The CDC25 PTPs are well-characterized phosphatases that function to dephosphorylate cyclin-dependent kinases at their inhibitory dually phosphorylated thr/tyr motifs. For further details on the PTPs, see the excellent review by Alonso et al. (2004).

Phospho-ser/thr-phosphatases (PSPs) are divided into three major families based on different catalytic mechanisms (PPPs, phosphoprotein phosphatases; PPMs, metal-dependent PPs; and FCP/SCP, aspartate-based phosphatases (Shi 2009)). Although the nomenclature may suggest otherwise, the catalytic mechanism employed by both PPPs and PPMs requires two metal ions (Fig. 2B). All PPP family members share a common catalytic domain, with ten absolutely conserved amino acids at the active site (Swingle et al. 2004). Six act to coordinate two metal ions (Fe/Zn) needed for the activation of a water molecule, which functions as the critical nucleophile during catalysis. The others position the incoming substrate for near perfect inline nucleophilic attack by the activated water (Swingle et al. 2004). PPMs are Mn2+/Mg2+-dependent phosphatases. PPMs evolved a different folding strategy to produce a similar catalytic mechanism that also utilizes metal ions in the activation of a water molecule for the dephosphorylation reaction (Shi 2009). Unlike PTPs, a covalent intermediate is not produced during the reaction. The aspartate-based catalysis mechanism utilized by FCP/SCP is different and may be limited to a limited number of substrates that contain random repeats of SYPTSPS (for review see Shi (2009)).

Based on the number of genes encoding proteins with phosphatase catalytic activity, PPMs represent the largest family of human PSPs. The PPM family included pyruvate dehydrogenase phosphatase and ~16 genes encoding >20 isoforms of the PP2C (Lammers & Lavi 2007). These enzymes are insensitive to natural inhibitors (i.e. okadaic acid, microcystin, cantharidin, and calyculin A), and the actions of most PPMs are poorly understood. However, due to their unique expression and subcellular localization patterns, most are predicted to act on a single substrate or limited substrates (Lammers & Lavi 2007).

The PPP family contains seven subfamilies (PPP1CA–PPP1C7B; Fig. 3), which are encoded by only 13 human genes yet together catalyze over 90% of all protein dephosphorylation occurring in eukaryotic cells (Moorehead et al. 2007, Virshup & Shenolikar 2009). Humans have three genes encoding four isoforms of PP1 (PPP1CA, PPP1CB, PPP1CC) with the two PPP1CC isozymes (called PP1Cγ1 and γ2) produced by alternate splicing of the PPP1CC gene. Two human genes encode nearly identical (98%) isoforms of PP2A (PPP2CA, PPP2CB). PP4 (PPP4C)
and PP6 (PPP6C) share 65% identity with PP2AC, but are encoded by distinct genes (Honkanen & Golden 2002). Humans express three highly homologous isoforms of PP2B/calcinierin (PP2Ba, PP2Bβ, and PP2Bγ) and two genes encode isoforms of PP7 (also called PPEF (PPEF1)). PP5 is unique in the respect that humans only express a single isoform of PP5. All PPP-family members are highly conserved in nature (e.g. the ortholog of PP2Aa in Neurospora crassa (bread mold) shares 87% amino acid identity with human PP2Aa). Figure 4 shows a structural comparison of PP1-MYPT1, PP2Ac-A-B, and PP5.

The ability of <15 gene products to counter ~90% of all cellular protein phosphorylation produced the lingering misconception that PPP family enzymes act as pleiotropic or simple housekeeping enzymes. More recently, this popular, yet erroneous, belief has given way to overwhelming data that indicate the actions of most PPPs are dynamic and highly regulated. What the early studies failed to reveal was that, although PPPs share a structurally related catalytic core and identical catalytic mechanisms, they function in the cell as multi-subunit protein complexes. In cells, each PPP family member can achieve many specific functions, because the protein encoded by a PPP gene represents a catalytic subunit that can interact with a distinct set of substrates and interaction proteins. PP1 and PP2A are the most studied, and to date nearly 200 PP1-interacting proteins have been validated (Heroes et al. 2013). These PP1-interacting proteins share little or no structural similarity beyond their PP1-interacting domains and many are only expressed in differentiated or highly specialized cells (Virshup & Shenolikar 2009, Heroes et al. 2013). Therefore, PP1 actually represents a vast array of PP1c-containing holoenzymes, in which the structurally unrelated binding partners control the subcellular localization, activity, and substrate specificity of PP1 (Bollen et al. 2010, Heroes et al. 2013).

PP2A, PP4, and PP6 also gain regulation and substrate specificity by assembling into a number of different multi-subunit holoenzymes that share a common catalytic subunit. For this family, PP2A is best studied. PP2A commonly functions as a three-protein holoenzyme. Most human cells express both the catalytic subunit (PP2Ac) and an A-subunit that functions as a scaffold to tether PP2Ac to a number of different regulatory/targeting B-subunits. In humans, there are 15 genes encoding four families of B-subunits that produce >21 B-isoforms, many of which are expressed only in certain types of cells or during different stages of development (Shi 2009, Virshup & Shenolikar 2009). The final composition of the PP2A-holoenzyme is then derived from the combinatorial assembly of one of the two isoforms of PP2Ac, one of the two isoforms of PP2A-A, and one of the >20 B-subunits (Virshup & Shenolikar 2009, Sents et al. 2013). Therefore, substrate specificity, subcellular targeting, and control of PP2A holoenzyme activity is usually regulated by assembly and mainly determined by the regulatory B-subunits (Virshup & Shenolikar 2009, Lambrecht et al. 2013, Sents et al. 2013). Similar regulatory, targeting, and control mechanisms are starting to emerge from studies of PP4 and

Figure 4
Structural comparison of PP1-MYPT1, PP2Ac/A–B, and PP5. (A) PP1 (green) in complex with myosin phosphatase targeting subunit MYPT1 (blue). (B) PP2A holoenzyme: PP2A catalytic subunit (green) in complex with the PP2A scaffold A (blue) and a B55-regulatory targeting subunit (yellow). (C) PP5 in an inactive conformation. The catalytic domain is shown in green, N-terminal inhibitory/TPR-targeting domain in yellow, and a unique C-terminal inhibitory domain in blue. The images were generated using PyMol based on protein data bank accession number 1S70 (Terrak et al. 2004; PP1-MYPT1), 3DW8 (Xu et al. 2008; PP2Ac/A/B), and 1WA0 (Yang et al. 2005; PP5). Arrows indicate the catalytic site with metal ions shown as red spheres.
PP6, which have their own scaffold and regulatory proteins (Chen et al. 2008, Couzens et al. 2013). In addition, there are a few examples (i.e. s4) in which interaction of certain B-type regulatory proteins are shared by PP2A, PP4, and PP6 (Chen et al. 1998, Kloecker et al. 2003, Breitkreutz et al. 2010).

PP2B, more commonly called calcineurin, is the target of cyclosporin A, which is useful in a clinical setting as a strong immunsuppressive agent. Both calcineurin and PP7 are insensitive to okadaic acid and microcystin (Huang & Honkanen 1998, Honkanen & Golden 2002), and both calcineurin and PP7 are regulated by calcium. For calcineurin, the catalytic-A subunit is maintained in an inactive/inhibited state by the binding of an inhibitory protein, commonly call calcineurin B. Calcineurin only becomes active upon Upon calcium-mediated association with Ca²⁺-bound calmodulin (Shi 2009). PP7 is also activated by calcium; however, the C-terminal domain of PP7 contains calmodulin-like and EF-hand-like domains that appear to directly bind Ca²⁺ (Huang & Honkanen 1998, Huang et al. 2000, Honkanen & Golden 2002). Calcineurin expression is high in brain, while the expression of PP7 is limited, mostly to retina (Huang & Honkanen 1998, Shi 2009).

PP5 is unique in the respect that the catalytic, regulatory, and substrate-targeting domains of PP5 are encoded by a single gene and expressed as a single polypeptide (Honkanen & Golden 2002, Golden et al. 2008). The catalytic core of PP5 is similar in structure to that of the catalytic subunit of PP1, PP2A, PP4, and PP6, and like these PSPs, PP5 is sensitive to inhibition by okadaic acid, calyculin A, cantharidin, and microcystins (Honkanen & Golden 2002, Swingle et al. 2004, 2007, Virshup & Shenolikar 2009). Indeed, the vast majority of the studies that use these natural inhibitors to study PPP actions in cells draw conclusions that implicate PP1 and PP2A in the processes that are being studied, failing to acknowledge that PP4, PP5, and PP6 are also widely expressed in human tissues and potently inhibited by these natural compounds (Swingle et al. 2004, 2007, Virshup & Shenolikar 2009). Unlike PP1 and PP2A, the catalytic activity of PP5 is minimal when PP5 is not associated in a complex with other proteins (Golden et al. 2008). This is because when PP5 is alone, the N-terminal domain of PP5 folds back over the catalytic site, producing an auto-inhibitory complex that blocks substrate access to the catalytic site (Golden et al. 2008). The N-terminal region of PP5 also contains three tetratricopeptide repeat (TPR) domains, which mediate the binding of PP5 to proteins that contain TPR-docking sites. The best studied interaction for PP5 is the interaction with heat shock protein 90 (HSP90; Skarra et al. 2011). PP5 binds HSP90 via interactions between the N-terminal TPR domains of PP5 and a C-terminal TPR-docking domain in HSP90 (Silverstein et al. 1997, Ramsey et al. 2000, Russell et al. 2006, Skarra et al. 2011). Upon binding, PP5 appears to undergo a conformational change allowing substrate access to the active site (Yang et al. 2005). To date, ~110 proteins have been identified with TPR-docking domains, suggesting that PP5 could also play many unique cellular roles. Currently, PP5 is known to affect stress, hormone- (i.e. glucocorticoid receptor (GR)) and metabolic-mediated signaling cascade (Amable et al. 2011, Skarra et al. 2011, Grankvist et al. 2012, 2013). However, the mechanism controlling PP5 interactions and activity remains largely unexplained.

**PPs in β-cell proliferation and apoptosis**

**Protein tyrosine phosphatases**

Protein tyrosine phosphatases (PTPs) are a superfamily of enzymes which oppose the roles of their protein tyrosine kinase counterparts (Andersen et al. 2001). In relation to β-cell apoptosis, PTPN2 (also known as TC-PTP or PTP-S2; a member of the first nontransmembrane subfamily of PTPs), has attracted interest. PTPN2 was identified a candidate gene for T1D, which is expressed in pancreatic β-cells (Ylipaasto et al. 2005, Todd et al. 2007). Furthermore, PTPN2 expression was regulated by cytokines (Cardozo et al. 2001, Moore et al. 2009). Transfection with PTPN2 siRNAs inhibited basal- and cytokine-induced PTPN2 expression in rat β-cells and dispersed human islets cells. Decreased PTPN2 expression exacerbated interleukin β (ILβ) + interferon γ (IFNγ)-induced β-cell apoptosis and turned IFNγ alone into a proapoptotic signal (Moore et al. 2009). Inhibition of PTPN2 amplified IFNγ-induced STAT1 phosphorylation, whereas double knockdown of both PTPN2 and STAT1 protected β-cells against cytokine-induced apoptosis, suggesting that STAT1 hyperactivation is responsible for the aggravation of cytokine-induced β-cell death in PTPN2-deficient cells (Moore et al. 2009). Further studies have shown that PTPN2 modulates pancreatic β-cell apoptosis via regulation of the BH3-only protein BIM (Santin et al. 2011). PTPN2 knockdown exacerbated type 1 IFN-induced apoptosis in INS1E, primary rat, and human β-cells. PTPN2 silencing and exposure to type 1 and 2 IFNs induced BAX translocation to the mitochondria, cytochrome c release, and caspase 3 activation. There was also an increase in BIM
phosphorylation that was at least in part regulated by JNK1. From these data, it can be concluded that PTPN2 confers cytoprotective effects to pancreatic β-cells. However, such an anti-apoptotic role of PTPN2 cannot be generalized to other PTPs.

In contrast to the anti-apoptotic role played by PTPN2, ablation of PTP1B increases β-cell proliferation in vivo (Fernandez-Ruiz et al. 2014). Morphometric analysis of pancreatic islets from Ptp1b−/− mice showed a higher β-cell area, concomitantly with higher β-cell proliferation and a lower β-cell apoptosis when compared with islets from their respective WT cognates (Fernandez-Ruiz 2014, #249). At a functional level, isolated islets from Ptp1b−/− mice exhibited enhanced glucose-stimulated insulin secretion. Moreover, Ptp1b−/− mice were able to partially reverse streptozotocin-induced β-cell loss, all indicating that inhibition of PTP1B expression in islet cells may be a therapeutic avenue to promote islet function.

PTP-BL is a nonreceptor PTP that is expressed in β-cells under the control of the MODYS gene product, HNF1β (Lee et al. 1999, Thomas et al. 2004). In mature β-cells HNF1β expression is low, but forced induction of HNF1β leads to enhanced rates of apoptosis, altered regulation of the cell cycle, and inhibition of stimulated insulin secretion in β-cells, suggesting that control of HNF1β expression may be important for the regulation of β-cell viability and function (Welters et al. 2006). Stably transfected insulin-producing cells, expressing the WT form of PTP-BL, display compromised cell proliferation but with no change in the rate of cell apoptosis (Welters et al. 2008). Furthermore, cells overexpressing PTP-BL were less responsive toward mitogenic stimulation by Wnt3a. Although only performed in a β-cell line, these data suggest that PTP-BL may play a role in the regulation of cell-cycle progression in β-cells, and that it interacts functionally with the components of the Wnt signaling pathway. Future studies are needed to determine whether PTP-BL plays a regulatory role during β-cell proliferation in vivo. For example, it will be interesting to determine whether forced expression of PTP-BL inhibits adaptive β-cell proliferation in response to reduced insulin sensitivity.

Ser/thr PP1

PP1 is regulated by its interaction with a variety of protein subunits that target the catalytic subunit (PP1C) to specific subcellular compartments and determines its localization, activity, and substrate selectivity (Cohen 2002). In the field of β-cell research, the PP1 regulatory subunit PPP1R15A has attracted special interest. PPP1R15A targets PP1 to the endoplasmic reticulum (ER) and is induced under conditions of ER stress (Rutkowski et al. 2006). The physiological response to ER stress is a collection of cellular events aiming to alleviate ER stress by decreasing overall protein synthesis through phosphorylation of the eukaryotic initiation factor 2α (eIF2α), through enhanced protein folding capacity by increased expression of chaperones and through activation of mechanisms for protein degradation (Ortsäter & Sjöholm 2007). The function of PPP1R15A is to serve as the regulatory subunit of the PP1A catalytic domain. Through their interaction, PPP1R15A and PP1C dephosphorylate eIF2α and thus exert a regulatory feedback that can allow for re-initiation of protein synthesis and thereby allows for the expression of stress-induced genes (Novoa et al. 2003). Inhibition of PP1-mediated dephosphorylation of eIF2α by the compound salubralin was found to be cytotoxic by itself in β-cells and in isolated islets of Langerhans. In addition, salubralin potentiated fatty acid-induced ER stress and apoptosis (Cnop et al. 2007, Ladriere et al. 2010). Besides being a part of ER-stress signaling, PP1 plays a pivotal role in glucose-induced stimulation of overall translation in β-cells, which depends on a PP1-mediated decrease in Ser51 phosphorylation of eIF2α (Vander Mierde et al. 2007). Thus, the steady-state level of eIF2α phosphorylation in β-cells is the result of a balance between folding-load-induced phosphorylation and PP1-dependent dephosphorylation. Because defects in the pancreatic ER kinase–eIF2α signaling system lead to β-cell failure and diabetes, deregulation of the PP1 system could likewise lead to cellular dysfunction and disease.

Ser/thr PP2A

The PP2A family of enzymes is a major class of ser/thr PPs. They are also one of the most abundant cellular proteins, accounting for ~1% of total cellular protein and some 80% of all cellular ser/thr PP activity (Janssens & Goris 2001, Shi 2009). Evidence suggests that PP2A activation can be linked to apoptosis, e.g. activation of caspase-3 causes cleavage of the regulatory A subunit of PP2A, which in turn increases PP2A activity (Santoro et al. 1998). As discussed below, PP2A may have a critical role in β-cell survival and demise. Exposure (for at least 24 h) of insulin-secreting cells to the phosphatase inhibitor, okadaic acid, at concentrations inhibiting PP1, PP2A, PP4, PP5, and PP6, reduces cell proliferation and insulin secretion. The reduced proliferation was found to be related to the induction of apoptosis as evident by morphological criteria and the occurrence of DNA fragmentation...
(Krauthheim et al. 1999). Of particular interest is that PP2A is hyper-activated by chronic exposure to high glucose (Arora et al. 2013) and ceramide (Kowluur & Metz 1997), which are both well-known inducers of β-cell apoptosis. In the case of glucose, it was found that siRNA-mediated knockdown of the catalytic subunit of PP2A (PP2Ac) markedly attenuates glucose-induced activation of PP2A (Arora et al. 2013). Moreover, metabolizable – but not non-metabolizable – glucose derivatives induce Leu309 methylation of the catalytic subunit of PP2A. As a consequence, knockdown of the cytosolic leucine carboxymethyl transferase 1 (LCMT1), which carboxymethylates PP2Ac, significantly attenuates PP2A activation induced by high glucose. It was also found that glucose exposure induced LCMT1 expression, as well as the PP2A regulatory subunit B55α. Taken together, the data indicate that high glucose exposure hyperactivates PP2A via the induction of the methylating enzyme LCMT1 and the regulatory subunit B55α. Recent experiments have established a link between glucose-induced activation of PP2A and nuclear import of forkhead box O1 (FOXO1) in β-cells (Yan et al. 2012). Under conditions of oxidative stress evoked by high glucose stimulation, FOXO1 associates with the PP2A holoenzyme composed of the catalytic C, structural A, and B55α regulatory subunits. Knockdown of B55α in INS1 cells reduced FOXO1 dephosphorylation, inhibited FOXO1 nuclear translocation, and attenuated oxidative stress-induced cell death (Yan et al. 2012). This mechanism may be relevant also in vivo because both B55α and nuclear Foxo1 levels were increased under hyperglycemic conditions in db/db mouse islets, an animal model of T2D (Yan et al. 2012). Taken together, these data tell us that PP2A may play a role for glucotoxicity in β-cells via dephosphorylation of FOXO1 and that prevention of PP2A hyperactivation may confer protection against glucotoxicity.

Ser/thr PP2B/calcineurin

PP2B or calcineurin is a two-subunit enzyme, with a 58- to 64-kDa catalytic and calmodulin-binding subunit – calcineurin A – that is tightly bound to a regulatory 19-kDa calcium-binding regulatory subunit – calcineurin B (Klee et al. 1988).

Calcineurin is a Ca2+-activated cytosolic phosphatase that is critical for antigen-stimulated T lymphocyte activation (Crabtree & Olson 2002). Therefore, pharmacologic calcineurin inhibition is highly effective in preventing allograft rejection. However, calcineurin is also expressed in β-cells (Tamura et al. 1995, Ebihara et al. 1996, Redmon et al. 1996), where it has two well-described molecular targets, the nuclear factor of activated T cell 2 family of transcription factors (Lawrence et al. 2001) and the cAMP-responsive element-binding protein (CREB) transcriptional co-activator, transducer of regulated CREB activity 2 (TORC2) (Screaton et al. 2004). Through dephosphorylation-mediated nuclear localization of these targets, calcineurin integrates Ca2+ and cAMP signals generated by physiologic stimuli, such as hyperglycemia and incretin receptor activation, to alter gene expression (Lawrence et al. 2001, 2002, Screaton et al. 2004). CREB is a cAMP- and Ca2+-responsive transcriptional activator that is required for β-cell proliferation and survival (Jhala et al. 2003, Inada et al. 2004, Hussain et al. 2006). Glucose and incretin hormones promote synergistic CREB activity by inducing the nuclear re-localization of TORC2, a co-activator for CREB (Screaton et al. 2004, Koo et al. 2005, Shaw et al. 2005). In islet cells, under basal conditions, when CREB activity is low, TORC2 is phosphorylated and sequestered in the cytoplasm by 14-3-3 proteins (Screaton et al. 2004). In response to feeding stimuli, TORC2 is dephosphorylated, enters the nucleus, and binds to CREB located at target gene promoters (Bittinger et al. 2004, Screaton et al. 2004, Koo et al. 2005). Ser275 of TORC2 is a 14-3-3 binding site that is phosphorylated under low-glucose conditions and which becomes dephosphorylated by calcineurin in response to glucose influx (Jansson et al. 2008). Dephosphorylation of Ser275 is essential for both glucose- and cAMP-mediated activation of CREB in β-cells and islets, demonstrating the essential role of calcineurin activity in β-cell physiology.

Given this role of calcineurin in β-cell biology, it is not surprising that pharmacologic calcineurin inhibition – necessary to prevent rejection in the setting of islet transplantation – is associated with post-transplant β-cell failure. New-onset diabetes mellitus after transplantation is a frequent complication after kidney transplantation, with an incidence of 15–30% (Cosio et al. 2002, Kasiske et al. 2003).

Several studies show that calcineurin inhibitors can target β-cells directly. Tacrolimus (FK506), a calcineurin inhibitor used in clinical practice to suppress islet graft rejection, induces β-cell apoptosis as evident by TUNEL staining in cultured human islets within 48 h of exposure (Selimanpour et al. 2010). This study identified insulin receptor substrate 2, a known CREB target and upstream regulator of the PI3K/Akt pathway, as a calcineurin target in β-cells. It was found that tacrolimus decreased Akt phosphorylation, suggesting that calcineurin could...
regulate replication and survival via the PI3K/Akt pathway (Soleimanpour et al. 2010). Similarly, rapamycin and cyclosporin A (also calcineurin inhibitors) decrease cell viability in human and rat pancreatic islets (Ozbay et al. 2011, Barlow et al. 2012) and in clonal insulin-producing cells (Plaumann et al. 2008). Mechanistically, calcineurin inhibition activates the dual leucine-zipper-bearing kinase (DLK), which in turn activates apoptotic MAPK signaling (Merritt et al. 1999, Plaumann et al. 2008). Human β-cell proliferation decreases exponentially with increasing age (Meier et al. 2008). Thus, studies of human β-cells, which are often carried out on islets from elderly donors, often fail to detect β-cell proliferation. Therefore, studies of β-cell proliferation are often carried out on β-cells obtained from rodent donors. In such studies, tacrolimus decreased β-cell proliferation by 72% in C57Bl/6 mice compared with vehicle-treated controls (Goodyer et al. 2012). These results lend support to experiments carried out in mice lacking calcineurin in β-cells (Heit et al. 2006). Mice with a β-cell-specific deletion of the calcineurin phosphatase regulatory subunit b1 develop age-dependent diabetes, characterized by decreased β-cell proliferation and mass, reduced pancreatic insulin content, and hypoinsulinemia. Moreover, β-cells lacking calcineurin activity have a reduced expression of established regulators of β-cell proliferation, such as MafA, Beta2, and Pdx1 (Heit et al. 2006). The impact of calcineurin on β-cell function is complex because, transgenic overexpression of active calcineurin in β-cells phenocopied mice with a β-cell-specific deletion of the calcineurin and resulted in decreased β-cell mass and hyperglycemia (Bernal-Mizrachi et al. 2010). These mice, which express a constitutively active form of calcineurin under the insulin gene promoter, exhibit glucose intolerance (Bernal-Mizrachi et al. 2010). In vitro studies of islets isolated from such mice demonstrated that decreased β-cell mass was accompanied by decreased proliferation and enhanced apoptosis (Bernal-Mizrachi et al. 2010). Taken together, these results demonstrate that pharmacological inhibition of calcineurin and genetic calcineurin deletion markedly inhibit rodent β-cell proliferation and promote β-cell apoptosis, which should be taken into account when treating patients in the need of immunosuppression. This may be especially important with patients displaying insulin resistance as the diabetogenic effect of tacrolimus, and cyclosporin A is more pronounced in insulin resistant obese rats (Rodriguez-Rodriguez et al. 2013).

While the vast majority of data suggest that calcineurin inhibition reduces β-cell viability and may cause a diabetes phenotype, the situation is different when it comes to β-cell death induced by either proinflammatory cytokines (Grunnet et al. 2009) or glucocorticoids (Ranta et al. 2006, 2008).

Treatment of isolated rats or human islets with cytokines promotes β-cell apoptosis by the intrinsic apoptotic pathway along with dephosphorylation of the proapoptotic protein BAD at ser136 (Grunnet et al. 2009). This particular serine residue is a target for calcineurin (Wang et al. 1999). In concordance, supplementation of tacrolimus to the cytokine-containing cell media prevented BAD dephosphorylation and cytokine-induced cytotoxicity (Grunnet et al. 2009), showing that – under these circumstances – calcineurin inhibition is favorable for β-cell viability.

The situation is similar under conditions of glucocorticoid exposure in culture. Although glucocorticoid-induced β-cell apoptosis has not been demonstrated in vivo, it is clear that these steroid hormones are cytotoxic to β-cells during ex vivo culture conditions (Ranta et al. 2006, 2008, Avram et al. 2008, Reich et al. 2012, Fransson et al. 2013). Glucocorticoids activate calcineurin, which in turn dephosphorylates the apoptotic protein BAD (Tumlin et al. 1997). Such a mechanism has also been demonstrated in insulin-producing cells (Ranta et al. 2006). Inhibition of calcineurin activity by tacrolimus and dexamethasone in insulin-secreting INS1 cells reduced apoptosis provoked by the synthetic glucocorticoid analog dexamethasone (Ranta et al. 2008). Thus, direct inhibition of calcineurin activity in β-cells decreases cell viability and reduces β-cell function. Of note, the situation is different for β-cell death induced by cytokines and glucocorticoids. In such cases, inhibition of calcineurin counteracts the cytotoxic effect of cytokines and glucocorticoids. Pharmacological inhibitors are never 100% specific, so these seemingly contradictory findings may be, at least partly, explained by effects that are independent of calcineurin. For example, tacrolimus can inhibit NF-κB activity, leading to the inhibition of NO formation (Tunon et al. 2003).

Ser/thr PP2C

Identification of PP2C isoforms traces back to the 1980s (Hiraga et al. 1981, Pato & Adelstein 1983). PP2C enzymes act on a variety of substrate classes, e.g. kinases, receptors, channels, and transcription factors, thereby affecting quite diverse physiological effects, e.g. stress response, metabolism, and cell cycle (Klumpp et al. 2006). In contrast to most other ser/thr PPs, inhibitors such as okadaic acid, microcystin, tautomycin, or inhibitor...
proteins I1 and I2 have no effect on PP2C isoenzymes. Hitherto PP2C isoforms have not been implicated in β-cell apoptosis. However, they are sensitive to stimulation by unsaturated fatty acids (Krieglstein et al. 2008). In this aspect, PP2C isoforms have been linked with fatty acid-induced apoptosis in neural and endothelial cells (Schwarz et al. 2006) and similar mechanisms may be operative in pancreatic β-cells.

Ser/thr PPs 4, 6, and 7

The ser/thr PPs 4, 6, and 7 have not been studied with regards to their possible implications in β-cell function. The catalytic subunit of PP4 is expressed in islets of Langerhans as evident by immunohistochemistry (http://www.proteinatlas.org), where it is located in the nucleus (Veluthakal et al. 2006). Neither PP6 nor PP7 catalytic subunit expression has been documented in β-cells.

Ser/thr PP5

PP5 is another member of the PPP family (Andreeva & Kutuzov 1999, Swingle et al. 2004) that is highly conserved among species and expressed in most, if not all, mammalian cells. However, the roles of PP5 in biology and disease are only beginning to emerge (Yong et al. 2007, Amable et al. 2011, Hinds et al. 2011), and the influence of PP5 on β-cell function is still unknown. The human gene encoding PP5 (PPP5C) is localized on chromosome 19 (Xu et al. 1996). PP5 has been reported to be present both in the nucleus and cytosol (Chinkers 2001). It has been proven difficult to study the biological role of PP5, partly because until recently, only a few physiological substrates have been identified. The polyunsaturated fatty acid, arachidonic acid, and the structural component of caveolae, caveolin-1, have both been shown to activate PP5 (Ramsey & Chinkers 2002, Taira & Higashimoto 2013). A high-throughput screening effort identified chaulmoogric acid as a compound that activate PP5 at fairly high concentrations (Cher et al. 2010). Suramin was identified as a novel PP5 activator by its competitively binding to a domain of PP5 and thereby causing its activation (Yamaguchi et al. 2013). During standard conditions, PP5 is predominately in an inactive state (Sinclair et al. 1999), causing a very low basal activity that represent <1% of the total measurable phosphatase activity. A unique characteristic of PP5 is that it is expressed as a single polypeptide, which consists of a phosphatase catalytic domain near its C-terminus and a regulatory domain at the N-terminus (Becker et al. 1994, Golden & Honkanen 2003). An additional feature, unique for PP5 among its family members, is the extended N-terminal region containing multiple TPR domains, by which PP5 mediates protein–protein interactions (Das et al. 1998). PP5 is associated with numerous proteins involved in diverse signaling networks, including Hsp90 complex with the GR (Chen et al. 1996, Silverstein et al. 1997), the cell division cycle (CDC16/CDC27/CDC37) subunits of the anaphase-promoting complex (Ollendorff & Donoghue 1997, Vaughan et al. 2008), cryptochrome 2 (Zhao & Sancar 1997), ataxia–telangiectasia and Rad3-related (Zhang et al. 2005) ataxia–telangiectasia and Rad3-mutated (Ali et al. 2004) DNA-dependent protein kinase catalytic subunit (Wechslers et al. 2004), apoptosis signal regulating kinase 1 (ASK1; Morita et al. 2001), Hsp90-dependent heme-regulated eIF2α kinase (Shao et al. 2002), Rac GTP-binding protein (Gentile et al. 2006), the A-regulatory subunit of PP2A (Lubert et al. 2001), Raf proto-oncogene ser/thr protein kinase (von Kriegsheim et al. 2006), stress-induced phosphoprotein 1 (Skarra et al. 2011), and the Gβ12/Gα13 subunits of heterotrimeric GTP-binding proteins (Yamaguchi et al. 2002).

PP5 has been recently shown for the first time to play a role in the β-cells (Grankvist et al. 2012). During the progression toward T2D, β-cells are often exposed to a combination of high levels of glucose and fatty acids, resulting in the production of the so-called glucolipotoxicity, which is associated with increased production of reactive oxygen species (ROS; Oprescu et al. 2007). In turn, increased levels of ROS cause initiation of apoptosis, resulting in a reduced β-cell mass (Butler et al. 2003). Several studies have indicated that PP5 is acting in the regulation of signaling cascades activated by oxidative stress.

Elevated levels of ROS can induce the association of PP5 with ASK1, leading to reduced ASK1 phosphorylation at Thr845, and thereby causing ASK1 inactivation (Morita et al. 2001, Huang et al. 2004, Zhou et al. 2004, Kutuzov et al. 2005). This suggests that PP5 can suppress the oxidative stress-induced apoptosis by averting sustained activation of ASK1 and its downstream target, JNK. PP5 may accordingly act as a negative regulator of the ASK1/JNK signaling pathway and in so doing protect cells from apoptosis (Morita et al. 2001, Kutuzov et al. 2005, Mkaddem et al. 2009). This concept was supported by the recent publication (Grankvist et al. 2012) indicating that islets from mice lacking PP5 were more susceptible toward stress-induced apoptosis than WT cognates. In addition, PP5-deficient mice had lower fasting glycemia and improved glucose tolerance compared with the WT
mice, suggesting a novel role for PP5 in the regulation of glucose homeostasis. These findings cannot be explained by a difference in islet mass between the PP5-deficient and WT mice, because no difference was observed (Grankvist et al. 2012). Furthermore, a high-fat diet treatment for 10 weeks revealed that the mice lacking PP5 gained markedly less weight, did not accumulate visceral fat, and displayed enhanced insulin sensitivity compared with the WT littermates (Grankvist et al. 2013). Another group (Hinds et al. 2011) also recently published studies indicating that embryonic fibroblasts from PP5 knockout mice did not accumulate lipids after adipogenic stimuli. Together, these studies suggest that PP5 may play a previously unrecognized role in both glucose and lipid metabolism. Nevertheless, additional studies are necessary to further address the role of PP5 in glucose homeostasis and \( \beta \)-cell function. Table 1 presents the summarized view on the role of different PPs in \( \beta \)-cell biology.

**Table 1** Summary of the protein phosphatases’ effects on pancreatic \( \beta \)-cells

<table>
<thead>
<tr>
<th>Protein name</th>
<th>Intervention</th>
<th>Biological material</th>
<th>Effect on ( \beta )-cells</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein tyrosine phosphatases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTPN2</td>
<td>Downregulation with siRNA</td>
<td>INS1E cells, rat, and human islets Mice</td>
<td>Promotes cytokine-induced apoptosis, enhanced PP2A activity and increased GSIS translation</td>
<td>Moore et al. (2009) and Santin et al. (2011)</td>
</tr>
<tr>
<td>PTP1B</td>
<td>Global genetic deletion</td>
<td>INS1 cells</td>
<td>Promotion of ( \beta )-cell proliferation and reduced insulin secretion</td>
<td>Fernandez-Ruiz (2014, #249)</td>
</tr>
<tr>
<td>PTP-BL</td>
<td>Stable over expression</td>
<td>INS1 cells</td>
<td>Compromised cell proliferation but no change in the rate of cell apoptosis</td>
<td>Welters et al. (2008)</td>
</tr>
<tr>
<td>Se/thr protein phosphatases</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ppp1R15A</td>
<td>Pharmacological inhibition by salubrinal</td>
<td>INS1E cells, rat, and human islets</td>
<td>Induce apoptosis and augmented fatty acid-induced apoptosis and controls glucose-mediated translation</td>
<td>Cnop et al. (2007), Vander Mierde et al. (2007) and Ladriere et al. (2010)</td>
</tr>
<tr>
<td>PP2A</td>
<td>High glucose or ceramide exposure</td>
<td>INS1 B32/13 cells and rat islets</td>
<td>Enhanced PP2A activity and loss of glucokinase</td>
<td>Kowluru &amp; Metz (1997) and Arora et al. (2013)</td>
</tr>
<tr>
<td>PP2A</td>
<td>High glucose exposure</td>
<td>INS1 and ( \beta )TC-3 cells</td>
<td>FOXO1 activation</td>
<td>Yan et al. (2012)</td>
</tr>
<tr>
<td>PP2B (calcineurin)</td>
<td>Pharmacological inhibition by tacrolimus, rapamycin, and cycloporsin A</td>
<td>Human and rat islets, MIN6 cells</td>
<td>Increased apoptosis</td>
<td>Plaumann et al. (2008), Soleimanpour et al. (2010), Ozbay et al. (2011) and Barlow et al. (2012) Goodyer et al. (2012)</td>
</tr>
<tr>
<td>PP2B (calcineurin)</td>
<td>Pharmacological inhibition by tacrolimus</td>
<td>CS7BI/6j mice ( \text{in vivo} )</td>
<td>Inhibition of ( \beta )-cell proliferation and development age-dependent diabetes alongside loss of ( \beta )-cell mass</td>
<td>Heit et al. (2006)</td>
</tr>
<tr>
<td>PP2B (calcineurin)</td>
<td>( \beta )-cell-specific genetic deletion</td>
<td>Mice</td>
<td>Develops age-dependent diabetes alongside loss of ( \beta )-cell mass</td>
<td>Bernal-Mizrachi et al. (2010)</td>
</tr>
<tr>
<td>PP2B (calcineurin)</td>
<td>( \beta )-cell-specific transgenic overexpression</td>
<td>Mice</td>
<td>Glucose intolerance and loss of ( \beta )-cell mass</td>
<td>Ranta et al. (2008) and Grunnnet et al. (2009)</td>
</tr>
<tr>
<td>PP2B (calcineurin)</td>
<td>Pharmacological inhibition by tacrolimus or delta-methrin</td>
<td>Human and rat islets</td>
<td>Attenuation of cytokine- and glucocorticoid-induced apoptosis</td>
<td>Grankvist et al. (2012) and Fransson et al. (2013)</td>
</tr>
<tr>
<td>PP5</td>
<td>Downregulation with siRNA or use of islets isolated from ( Ppp5C ) mouse</td>
<td>MIN6 cells and mouse islets</td>
<td>Promotes glucocorticoid- and palmitate-induced apoptosis</td>
<td>Grankvist et al. (2012, 2013)</td>
</tr>
<tr>
<td>PP5</td>
<td>Global genetic deletion</td>
<td>MIN6 cells and mouse islets</td>
<td>Improves glucose tolerance</td>
<td></td>
</tr>
</tbody>
</table>

**PPs and islet hormone secretion**

Significant changes in protein kinase activities and in protein phosphorylation patterns occur subsequent to the stimulation of \( \beta \)-cell insulin release by nutrients (Newgard & McGarry 1995, Jones & Persaud 1998, Sjoholm 1998). Therefore, the molecular mechanisms regulating phosphorylation by protein kinases of proteins involved in the insulin secretory process by the \( \beta \)-cell have been extensively investigated. However, far less is known about the role and regulation of protein dephosphorylation by various PPs.

While early investigators reported the presence of phosphatase activity in pancreatic islets (Taljedal 1967, Lipson et al. 1979, Lernmark et al. 1980, Colca et al. 1984), the identity of these enzymes was unknown at the time. More contemporary studies have established that i) the \( \beta \)-cell contains ser/thr and tyrosine PP activity
(Gagliardino et al. 1991, Sjöholm et al. 1993b, Chen & Ostenson 2005); ii) stimulation of protein phosphorylation by direct activation of PKA and PKC with forskolin or phorbol ester, respectively, results in a stimulated insulin secretion (Sjöholm 1991, Arkhammar et al. 1994, Hisatomi et al. 1996); iii) physiological stimuli of insulin secretion increase β-cell phosphorylation state (Jones & Persaud 1998); and iv) short-term treatment of β-cells or permeabilized rat pancreatic islets with the specific PP inhibitor okadaic acid promotes Ca^{2+} entry and insulin exocytosis (Ämmälä et al. 1994, Haby et al. 1994, Hisatomi et al. 1996, Larsson et al. 1997). These combined findings point to an important functional role for protein (de)phosphorylation in regulation of the stimulus–secretion coupling in the β-cell. The role of PPs in β-cell function and insulin secretion is nonetheless poorly understood.

Ser/Thr-PPases

Identification and characterization  PPP types 1 and 2A were identified in crude RINm5F β-cell homogenates by both enzymatic assay and western blot analysis (Sjöholm et al. 1993b). They were also characterized in terms of their sensitivity to the inhibitory actions of several compounds isolated from cyanobacteria, marine dinoflagellates, and marine sponges, (viz. okadaic acid, microcystin-LR, calyculin-A, and nodulin). It was found that okadaic acid was the least potent inhibitor (IC_{50} \approx 10^{-9} \text{ M} and IC_{100} \approx 10^{-6} \text{ M}), while the other compounds exhibited IC_{50} values of \approx 5 \times 10^{-10} \text{ M} and IC_{100} \approx 5 \times 10^{-9} \text{ M} (Sjöholm et al. 1993b).

Role in insulin stimulus–secretion coupling The mechanisms that regulate insulin secretion were electrophysiologically investigated in single β-cells (Haby et al. 1994). The secretory responses were substantially increased by conditions that promote protein phosphorylation, such as activation of protein kinases A and C or inhibition of PPP family members (PP1, PP2A, and PP4–PP6) by okadaic acid. These results suggest that, although Ca^{2+} is required for the initiation of exocytosis, modulation of exocytosis by protein kinases and phosphatases is of much greater quantitative importance. Similar findings were reported by other groups (Mayer et al. 1994). It should be noted, however, that not all investigators have arrived at this conclusion (Tamagawa et al. 1992, Ammon et al. 1996, Murphy & Jones 1996, Sato et al. 1998, Krauthem et al. 1999). In some of these studies, PP inhibitors (e.g. okadaic acid) were added to intact cells, sometimes for long periods of time. It is important to keep in mind that inhibitors such as okadaic acid may exert non-specific effects and toxicity when added to intact cells. The agent is known to interfere with membrane integrity by non-specific mechanisms. Loss of membrane integrity will disrupt, for instance the Ca^{2+} gradient over the membrane, causing massive uncontrolled Ca^{2+} influx that may cause apoptosis. A more physiologic way of studying the roles of PP by using inhibitors is to apply these acutely to permeabilized cells or in patch clamp settings, in which Ca^{2+} gradients are not operative. Indeed, the inhibitory effect of okadaic acid on GSIS in intact cells was mimicked by the inactive analog 1-nor-okadaone; in contrast, okadaic acid stimulated insulin secretion from permeabilized cells (Ratcliff & Jones 1993).

In one study, it was shown that the inhibitory effect of leptin on insulin secretion in rat and human islets is associated with decreased expression and activation of a PP1-like enzyme (Ruehnen et al. 2011).

In another study (Sjöholm et al. 1995), the effects of known insulin secretagogues and intracellular second messengers on the activities of cation-independent ser/thr PPs in insulin-secreting RINm5F β-cells were investigated. The stimulation of intact RINm5F cells with the insulin secretagogues, l-arginine, l-glutamine, K^+, or extracellular ATP elicited time-dependent changes in PPP activities with an early decrease in type 1-like and/or type 2A-like PPP activity that gradually returned to normal levels. Addition of cAMP, cGMP, or prostaglandins E_2 and F_1α at widely different concentrations to RINm5F cell homogenates failed to affect PPP activities. In contrast, addition of physiological concentrations of adenine nucleotides, known to increase upon nutrient stimulation, to RINm5F β-cell homogenates inhibited PP2A-like and, to a lesser extent, PP1-like PPP activity. It was concluded that insulin secretagogues cause time- and concentration-dependent inhibitory effects on RINm5F β-cell PPP activities, which may contribute to the increase in the phosphorylation state that occurs after stimulation of insulin release (Sjöholm et al. 1995). Thus, inhibition of protein dephosphorylation may be a regulatory mechanism controlling the stimulus–secretion coupling in insulin-producing cells. However, there are also contradictory findings: Murphy & Jones (1996) reported that PP1/2A was stimulated by glucose and required for GSIS in rat islets. The reasons for these discrepancies remain unknown at this time, but may relate to different models used.

In another study (Sjöholm et al. 2002), it was demonstrated that glycolytic and Krebs cycle intermediates, whose concentrations increase upon glucose stimulation, not only dose dependently inhibited ser/thr PP...
enzymatic activities but also directly promote insulin exocytosis from permeabilized β-cells. Thus, fructose-1,6-bisphosphate, phosphoenolpyruvate, 3-phosphoglycerate, citrate, and oxaloacetate inhibited PPPs and significantly enhanced insulin exocytosis, non-additive to that of okadaic acid, at micromolar Ca\textsuperscript{2+} concentrations. In contrast, the effect of GTP was potentiated by okadaic acid, suggesting that the action of GTP does not require PPP inactivation. It was concluded that specific glucose metabolites and GTP inhibit β-cell PP activities and directly stimulate Ca\textsuperscript{2+}-independent insulin exocytosis. The glucose metabolites, but not GTP, seem to require PP inactivation for their stimulatory effect on exocytosis. Thus, an increase in phosphorylation state, through inhibition of protein dephosphorylation by metabolic intermediates, may link glucose sensing to insulin exocytosis in the β-cell.

Although disputed (MacDonald & Fahien 2000), a messenger role has been postulated for l-glutamate in linking glucose stimulation to sustained insulin exocytosis in the β-cell (Maechler & Wollheim 1999), but the precise nature by which l-glutamate controls insulin secretion remains elusive. Effects of l-glutamate on the activities of PPPs and Ca\textsuperscript{2+}-regulated insulin exocytosis in INS1E β-cells were investigated (Lehtihet et al. 2005). Glucose was found to increase l-glutamate contents and promote insulin secretion from INS1E cells. l-glutamate also dose dependently inhibited PP enzyme activities, mimicking the specific PPP inhibitor, okadaic acid. l-glutamate and okadaic acid directly and non-additively promoted insulin exocytosis from permeabilized INS1E cells in a Ca\textsuperscript{2+}-independent manner. Thus, an inhibition of protein dephosphorylation by glucose-derived l-glutamate may link glucose sensing to sustained insulin exocytosis.

It has been additionally demonstrated that inositol hexakisphosphate (InsP\textsubscript{6}), whose concentration in β-cells transiently increases upon glucose stimulation (Larsson et al. 1997), dose dependently and differentially inhibits enzyme activities of ser/thr PPPs in physiologically relevant concentrations (Lehtihet et al. 2004). However, and in contrast to previous findings in rat islets (Gagliardino et al. 1997), none of the hypoglycemic sulfonfonylureas (glipizide, glibenclamide, and tolbutamide) affected PP1 or PP2A activity at clinically relevant concentrations in RINm5F cells. The reasons for this discrepancy remain elusive at this time; however, in part they may be due to different cell subclones, experimental conditions, and phosphoprotein substrates used.

The insulin secretagogue l-arginine, an immediate metabolic precursor to polyamines, was reported to cause a rapid and transient decrease in PP1 activity in RINm5F β-cells (Sjöholm et al. 1995). It was previously reported that polyamines dose dependently suppress PP1-like activity when added to RINm5F cell homogenates at physiologic concentrations, while having minor and inconsistent effects on PP2A-like activity (Sjöholm & Honkanen 2000). The IC\textsubscript{50} value for spermine on PP1-like activity was ~4 mM. The inhibitory effect was reproduced and of comparable magnitude on purified PP types 1A and 2A. On the other hand, when endogenous polyamine pools were exhausted by 4 days of exposure to the specific L-ornithine decarboxylase inhibitor D,L-α-difluoromethylornithine (Sjöholm et al. 1993a), there was an increase in PP2A-like activity. Quantitative western analysis revealed that the amount of PP2A protein did not change after this treatment. It was concluded that polyamines cause time-and concentration-dependent inhibitory effects on the PP activities of RINm5F β-cell, which may contribute to the increase in phosphorylation state that occurs after secretory stimulation. Figure 5 shows the proposed model of PPP regulation of insulin stimulus-secretion coupling.

Elegant work by the Kowluru laboratory has elucidated in great detail how PP2A is regulated (Kowluru 2005). The catalytic subunit of PP2A is subject to several means of post-translational modification: i) reversible carboxylmethylation at Leu\textsuperscript{309}, catalyzed by a PP methyltransferase, results in activation of the enzyme, holoenzyme assembly, and substrate association (Kowluru et al. 1996). As ebelactone, an inhibitor of methyl esterases, not only delayed demethylation of PP2A but also decreased GSIS, a negative role was suggested for PP2A in normal rat islet GSIS (Kowluru et al. 1996). On the other hand, genetic silencing of the catalytic subunit of PP2A in INS1 832/13 insulinoma cells by siRNA was found to abrogate GSIS (Jangati et al. 2007). Carboxylmethylation of the catalytic subunit of PP2A was inhibited by certain glucose metabolites and by increased cytosolic Ca\textsuperscript{2+} (Palanivel et al. 2004), leading to inactivation of the enzyme. It was suggested that this mechanism facilitates hyperphosphorylation of exocytotic proteins, thereby augmenting insulin secretion. ii) Phosphorylation at Tyr\textsuperscript{307} has been shown to inhibit PP2A catalytic activity, whereas nitration of Tyr\textsuperscript{307} alleviates the enzyme from inactivation by phosphorylation (Kowluru & Matti 2012). iii) Phosphorylation at Thr\textsuperscript{304} results in inactivation of PP2A (Kowluru & Matti 2012).

Not only secretion, but also protein synthesis, may also be translationally regulated by reversible phosphorylation. It was suggested that glucose-stimulated
translation in the β-cell requires a PP1-mediated decrease in Ser51 phosphorylation of eIF2α, an important factor controlling translational fidelity (Vander Mierde et al. 2007). In addition, in INS1 832/13 cells, glucose dephosphorylates elongation factor 2, probably through activation of PP2A (Yan et al. 2003). This suggests that INS1 832/13 cell protein translation rates are controlled by glucose-induced reversible phosphorylation of elongation factor 2.

Control of transcription factors may also be regulated by reversible phosphorylation: in INS1E cells, high glucose downregulates the expression of PPARα, leading to decreased fatty acid oxidation, through activation of PP2A and inactivation of AMPK, a cellular energy gauge (Ravnskjær et al. 2006). Also other important enzymes of critical regulatory role in GSIS appear regulated by phosphorylation. For instance, acetyl-CoA-carboxylase – which catalyzes malonyl-CoA formation – was found to be activated by magnesium and glutamate probably through an okadaic acid-sensitive PP2A-like enzyme (Kowluru et al. 2001), an effect that may stimulate β-cell anaplerosis through provision of long-chain fatty acids.

PP2B (calcineurin) has also been implicated in the control of islet hormone secretion: Renstrom et al. (1996) showed that the inhibitory effect of several neurotransmitters known to inhibit insulin secretion depicted. See text for details. AC, adenylyl cyclase; DAG, diacylglycerol; ER, endoplasmic reticulum; G, GTP-binding protein; Gln, glutamine; Glu, glutamate; GLUT2, glucose transporter 2; GTP, guanosine triphosphate; InsP₃, inositol trisphosphate; InsP₆, inositol hexakisphosphate; KᵥATP, ATP-dependent K⁺ channel; OA, okadaic acid; PIP₂, phosphatidylinositol bisphosphate; PKC, protein kinase C; PLC, phospholipase C; PP, protein phosphatase; R, receptor; TPA, 12-O-tetradecanoyl phorbolacetate; VGCC, voltage-gated Ca²⁺ channel.
(viz. somatostatin, galanin, and epinephrine) was associated with an activation of PP2B. Conversely, this inhibition of secretion was prevented by PP2B inhibitors. As PP2B inhibitors (e.g. cyclosporine-A) are used in islet transplantation for immunosuppressive purposes, the physiological role of the enzyme in islets is clinically very relevant. While short-term PP2B inhibition stimulates insulin secretion (Ebihara et al. 1996), long-term inhibition of the enzyme – or overexpression of its inhibitory regulators (Peiris et al. 2012) – may cause β-cell functional suppression and demise (Sjöholm 1994). PP2B is also required for proper cAMP-stimulated gene transcription in HIT β-cells (Schwaninger et al. 1995).

**Phosphotyrosine phosphatases**

Vanadate inhibits most PTPs and has been shown to exert direct glucose-dependent insulinotropic effects in isolated rodent islets by mechanisms involving phosphoinositide hydrolysis and Ca²⁺ handling (Fagin et al. 1987, Zhang et al. 1991). Interestingly, vanadium salts have also been found to exert anti-diabetic and islet-protective effects in various and widely different diabetic animal models, such as streptozotocin (Pederson et al. 1989), 90% pancreatectomy (Nakamura et al. 1995), and Zucker diabetic fatty rats (Winter et al. 2005), adding further credence to PTPs as inhibitors of insulin secretion also in vivo.

The PTPs IA-2 (ICA-512) and IA-2β (phogrin) are major autoantigens in T1D (Torii 2009), located in secretory granules, but developmentally differentially regulated. Whereas expression of phogrin appears insensitive to factors that influence β-cell function, IA-2 expression seems regulated by glucose, cAMP, and autocrine insulin (Lobner et al. 2002). In vivo, genetic disruption of IA-2 or phogrin results in glucose intolerance due to impaired insulin secretion (Henquin et al. 2008). However, it is likely that both enzymes are regulating the stability and/or loading of secretory granules, rather than influencing the exocytotic process per se. Thus, the main effects of PTPs on insulin secretion seem inhibitory.

**PPs and diabetes**

Surprisingly, little is known regarding the role of different PP in islets in diabetic states, in spite of the fact that PTPs IA-2 and phogrin are important autoantigens in T1D. Nonetheless, work from the Östenson laboratory (Östenson et al. 2002) reported a 60% overexpression of PTP σ in the islets of Goto–Kakizaki rats, a lean genetic model of T2D. Importantly, downregulation of PTPσ led to increased GSIS in these normally ‘glucose-blind’ islets. The authors concluded that increased expression of PTPσ may be of pathogenetic significance for the defective insulin secretion in GK rat islets. Interestingly, the same group reported that genetic variation in receptor PTPσ is associated with T2D in Swedish Caucasians (Langberg et al. 2007).

Another connection to both T1D and T2D may be ceramide, which is formed during sphingomyelin breakdown by proinflammatory cytokines such as IL1 (Mullen et al. 2012). Ceramide may inhibit β-cell mitogenesis and insulin production (Sjöholm 1995), possibly through the activation of JNK and the transcription factor ATF2 (Welsh 1996). Many effects of ceramide are believed to be mediated by a ceramide-activated PPP (CAPP), a PP2A-like enzyme expressed in islets (Kowluru & Metz 1997). The genetic silencing of the α isofrom of the PP2A catalytic subunit, achieved through siRNA knockdown, was found to significantly reduce CAPP enzymatic activity in INS 832/13 cells (Jangati et al. 2006).

The Kowluru lab also reported that the catalytic subunit of PP4, present in INS1 cell nuclei, can be regulated by IL1 the following: exposure of the INS1 cells to IL1 led to the expected increase in NO formation, but also reduced the expression, carboxylmethylation, and enzymatic activity of PP4 (Veluthakal et al. 2006). PP4 catalytic subunit was found to form complex with nuclear lamin-B, which regulates nuclear envelope assembly. The authors proposed that IL1/NO-induced inhibition of PP4 expression and enzymatic activity may aid keeping lamin-B phosphorylated and thereby make it amenable for pro-apoptotic caspases that may lead to β-cell death (Veluthakal et al. 2006).

This effector system may also be relevant in T2D, as studies have shown that cytokines such as IL1 are produced by islet cells and increased by glucotoxicity (Maedler et al. 2002). Another connection between T2D and ceramide is the lipotoxicity prevailing in T2D. While IL1-induced ceramide is formed from sphingolipids, islet ceramide accumulating under conditions of hyperlipidemia appears to be derived from de novo synthesis from free fatty acids (FFAs; Shimabukuro et al. 1998). Thus, islet ceramide and CAPP may be increased by two different mechanisms in T2D: a glucotoxic pathway involving paracrine/autocrine IL1 promoting sphingomyelin breakdown and a lipotoxic pathway in which ceramide is generated from FFAs. These two pathways, which normally potentiate each other's toxicity, may thus additively or synergistically activate islet CAPP.
In islets of T2D Goto–Kakizaki rats, the magnesium and glutamate-sensitive PP2A-like enzyme mentioned earlier (Kowluru et al. 2001) appears to be dysregulated, in that the activation of ACC by magnesium and glutamate seems to be markedly reduced (Palanivel et al. 2005). The pathophysiological relevance of this derangement is unclear at this time, but could conceivably result in reduced formation of long-chain fatty acids and contribute to the loss of GSIS in this widely used animal model.

Elegant studies from the Kowluru laboratory have provided in-depth mechanistic insights into the role of PP2A in islets under diabetes-like glucotoxic conditions (Arora et al. 2013). During chronic hyperglycemia, mimicked by high glucose in vitro, PP2A becomes hyperactivated – an effect coupled to loss of GSIS. Knockdown by siRNA of the PP2A catalytic subunit prevented this hyperactivation. Also, glucose, but not non-metabolizable sugars, augmented the carboxymethylation of Leu307 of the catalytic subunit (Arora et al. 2013).

High glucose increased the expression of a regulatory subunit of PP2A, which has been implicated in islet dysfunction during glucotoxicity. No clear role for ER stress in glucose-induced activation of PP2A could be found. Authors proposed that exposure of the β-cell to high glucose results in exaggerated PP2A activity and subsequent loss of GSIS.

Future prospects

To understand how protein dephosphorylation is regulated within the islet and how this controls hormone secretion, apoptosis, and proliferation, thorough and deep mechanistic studies are clearly needed. With the exception of PP5, which is the only member of the PPP family with the catalytic and regulatory subunit encoded by one gene, knockdown strategies targeting the catalytic subunits will not probably be a fruitful avenue to follow in order to explore the function of ser/thr PPs. Elimination of the regulatory subunits is likely to be more exact in targeting specific cellular functions. Knockdown experiments should be followed by an investigation of changes in the phosphoproteome to further pinpoint which proteins that are targeted. Furthermore, characterization of the different PSPs/PTPs expressed in the various islet cell types may prove important not only from a diabetes pathogenic perspective but may also offer clues to development of novel antidiabetic drugs.

References


Chen MS, Silverstein AM, Pratt WB & Chinkers M 1996 The tetratrico-peptide repeat domain of protein phosphatase 5 mediates binding to high-density oligonucleotide arrays. Diabetes 55 312271a0.
Chen J & Ostenson CG 2005 Inhibition of protein-tyrosine phosphatases targets. EMBO Journal 24 1043–1046. (doi:10.1038/sj.emboj.1900702)
Chen J & Ostenson CG 2005 Inhibition of protein-tyrosine phosphatases targets. EMBO Journal 24 1043–1046. (doi:10.1038/sj.emboj.1900702)
Fischer EH, Graves DJ, Crittenden ER & Krebs EG 1959 Structure of the site phosphorylated in the phosphorylase b to a reaction. Journal of Biological Chemistry 234 1698–1704.


Nature Cell Biology 8 1011–1016. (doi:10.1038/nbc16465)


Kutuzov MA, Andreava AE & Vyoyn-Yasenetskaya TA 2005 Regulation of apoptosis signal-regulating kinase 1 (ASK1) by polyamine levels via protein phosphatase 5. 

Journal of Biological Chemistry 280 25388–25395. (doi:10.1074/jbc.M413202200)


Methods in Molecular Biology 1053 283–305.


Langberg EC, Gu HF, Nordman S, Efendic S & Ostenson CG 2007 Genetic variation in receptor protein tyrosine phosphatase sigma is associated with type 2 diabetes in Swedish Caucasians. 


Science 278 471–474. (doi:10.1126/science.278.5337.471)

Lawrence MC, Bhatt HS, Watterson JM & Easom RA 2001 Regulation of insulin gene transcription by a Ca(2+)-responsive pathway involving calcineurin and nuclear factor of activated T cells. 

Molecular Endocrinology 15 1758–1767. (doi:10.1210/mend.15.10.07002)


Diabetes 51 691–698. (doi:10.2337/diabetes.51.3.691)

Lee YC & Nielsen JH 2009 Regulation of β-cell replication. 


Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Lee JH, Han SY, Lee HK, Park JY, Oh RR et al. 1999 Immunohistochemical localization of FAP-1, an inhibitor of Fas-mediated apoptosis, in normal and neoplastic human tissues. 


Lehtimäki, Honkanen RE & Sjöholm A 2004 Inositol hexakisphosphate and sulfonfureas regulate β-cell protein phosphatases. 


Biochimica et Biophysica Acta 602 130–135. (doi:10.1016/0005-2736(80)90210-9)

Lipson LG, Siegel E, Wollheim CB & Sharp GW 1979 Insulin release during fasting: studies on adenylate cyclase, phosphodiesterase, protein kinase, and phosphoprotein phosphatase in isolated islets of Langerhans of the rat. 

Endocrinology 105 702–707. (doi:10.1210/endo-105-3-702)


Plaumann S, Blume R, Borchers S, Steinfeldor HF, Knevel W & Oetjen E 2008 Activation of the dual-leucine-zipper-bearing kinase and induction of
β-cell apoptosis by the immunosuppressive drug cyclosporin A. Molecular Pharmacology 73 652–659. (doi:10.1124/mol.107.040782)


Reich E, Tamary A, Sionov RV & Melloul D 2012 Involvement of the Ca(2+)-dependent heme-regulated eIF2α kinase. Biochemistry 41 6770–6779. (doi:10.1021/bi205737a)


Shao J, Hartson SJ & Mats RL 2002 Evidence that protein phosphatase 5 functions to negatively modulate the maturation of the Hsp90-dependent heme-regulated eIF2α kinase. Biochemistry 41 6770–6779. (doi:10.1021/bi205737a)


Welsl N 1996 Interleukin-1β-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F. *Journal of Biological Chemistry* **271** 8307–8312. (doi:10.1074/jbc.271.4.2121)


Received in final form 13 March 2014
Accepted 27 March 2014
Accepted Preprint published online 28 March 2014